Search bioRxiv⌕ Search

Biology subjects

Borst, G.

Publications and source records attributed to Borst, G..

2 recordsLinked to original sources

DeepPathway: Predicting Pathway Expression from Histopathology Images

Spatial transcriptomics (ST) technologies provide spatially resolved gene expression along with image data, allowing the integrative analysis of complex tissue microenvironments. Despite their potential, the widespread adoption of ST remains limited due to high costs, and methodological challenges in data acquisition. Thus, there have been recent efforts to develop deep learning methods capable of inferring spatial gene expression from the much cheaper and easily available haematoxylin and eosin (H&E) images. These methods demonstrate promising results in reconstructing transcriptomic landscapes within tissue sections. While existing approaches predominantly focus on gene-level predictions, biological processes are often regulated at the pathway level through coordinated activity among functionally related genes. We present DeepPathway, a contrastive learning-based approach trained on ST data to predict pathway expression from H&E-stained sections. We compute input pathway expression by summarizing the expression of constituent genes using established pathway definitions. We evaluate the performance of our method on two prostate cancer datasets and validate our approach on the H&E images acquired from The Cancer Genome Atlas (TCGA) clearly differentiating between normal and tumour tissues. Finally, we apply our method to predict hypoxia signatures using H&Es of brain tumour samples where hypoxia staining with pimonidazole was available as ground truth. Implementation code for DeepPathway is available at https://github.com/aahsan045/DeepPathway.

bioinformatics↗

Radiosensitivity is an acquired vulnerability of PARPi-resistant BRCA1-deficient tumors

The homologous recombination (HR) defect in BRCA1-associated cancers can be therapeutically exploited by the treatment with DNA-damaging agents and poly (ADP-ribose) polymerase (PARP) inhibitors. We and others previously reported that BRCA1-deficient tumors are initially hypersensitive to the inhibition of topoisomerase I/II and PARP, but acquire drug resistance through restoration of HR activity by the loss of end-resection antagonists of the 53BP1/RIF1/REV7/Shieldin/CST pathway. Here, we identified radiotherapy as an acquired vulnerability of 53BP1;BRCA1-deficient cells in vitro and in vivo. In contrast to the radioresistance caused by HR restoration through BRCA1 reconstitution, HR restoration by 53BP1 pathway inactivation further increases radiosensitivity. This highlights the relevance of this pathway for the repair of radiotherapy-induced damage. Moreover, our data show that BRCA1-mutated tumors that acquired drug resistance due to BRCA1-independent HR restoration can be targeted by radiotherapy.\n\nSTATEMENT OF SIGNIFICANCEIn this study, we uncovered radiosensitivity as a novel therapeutically exploitable vulnerability of BRCA1-deficient mouse mammary cells that have acquired drug resistance due to the loss of the 53BP1 pathway.

cancer biology↗